Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Kagota, Satomi ^a   Maruyama, Kana ^a   McGuire, John J ^b  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 2;

BLOOD FLOW; BLOOD PRESSURE; CARDIOVASCULAR RISK; CELL METABOLISM; CELLULAR DISTRIBUTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE; VASODILATATION; ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS; ENDOTHELIUM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RAT;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS; ENDOTHELIUM; HUMANS; METABOLIC SYNDROME X; OBESITY; RATS; RECEPTOR, PAR-2;

EID: 84960970579     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/3130496     Document Type: Review

References (89)

1. P. Dandona,A. Aljada, A. Chaudhuri, P. Mohanty, and R. Garg, "Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation," Circulation, vol. 111, no. 11, pp. 1448-1454, 2005.
2. P. M. Vanhoutte, "Endothelial dysfunction in hypertension," Journal of Hypertension, Supplement, vol. 14, no. 5, pp. S83-S93, 1996.
3. S. Nystedt, K. Emilsson, A.-K. Larsson, B. Strombeck, and J. Sundelin, "Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2," European Journal of Biochemistry, vol. 232, no. 1,pp. 84-89, 1995.
4. S. Nystedt, A.-K. Larsson, H. Aberg, and J. Sundelin, "The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression,"The Journal of Biological Chemistry, vol. 270, no. 11, pp. 5950-5955, 1995.
5. F. Samad andW. Ruf, "Inflammation, obesity, and thrombosis," Blood, vol. 122, no. 20, pp. 3415-3422, 2013.
6. M. D. Hollenberg and J. Trejo, Proteinase-Activated Receptors: PAR2, IUPHAR/BPS Guide to Pharmacology, 2015.
7. M. Saifeddine, B. Al Ani, C.-H. Cheng, L. Wang, and M. D. Hollenberg, "Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue," British Journal of Pharmacology, vol. 118, no. 3, pp. 521-530, 1996.
8. F. Syeda, J. Grosjean, R. A. Houliston et al., "Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogenactivated protein kinase and NF-B pathways," The Journal of Biological Chemistry, vol. 281, no. 17, pp. 11792-11804, 2006.
9. F. Bono, I. Lamarche, and J. M. Herbert, "Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2)," Biochemical and Biophysical Research Communications, vol. 241, no. 3, pp. 762-764, 1997.
10. J. C. Hennessey, B. D. Stuyvers, and J. J. McGuire, "Small caliber arterial endothelial cells calciumsignals elicited by PAR2 are preserved from endothelial dysfunction," Pharmacology Research & Perspectives, vol. 3, no. 2,Article ID e00112, 2015.
11. R. Ramachandran, F. Noorbakhsh, K. Defea, and M. D. Hollenberg, "Targeting proteinase-activated receptors: therapeutic potential and challenges," Nature Reviews Drug Discovery, vol. 11, no. 1, pp. 69-86, 2012.
12. K. A. DeFea, J. Zalevsky, M. S. Thoma, O. Dery, R. D. Mullins, and N. W. Bunnett, "βrrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2," Journal of Cell Biology, vol. 148, no. 6, pp. 1267-1281, 2000.
13. M. Saifeddine, M. El-Daly, K. Mihara et al., "GPCR-mediated EGF receptor transactivation regulates TRPV4 action in the vasculature," British Journal of Pharmacology, vol. 172, no. 10, pp. 2493-2506, 2015.
14. J.-S. Joyal, S. Nim, T. Zhu et al., "Subcellular localization of coagulation factor II receptor-like 1 in neurons governs angiogenesis," Nature Medicine, vol. 20, no. 10, pp. 1165-1173, 2014.
15. K. Mihara, R. Ramachandran, B. Renaux, M. Saifeddine, andM. D. Hollenberg, "Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1)," The Journal of Biological Chemistry, vol. 288, no. 46, pp. 32979-32990, 2013.
16. M. D. Hollenberg, K. Mihara, D. Polley et al., "Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease," British Journal of Pharmacology, vol. 171, no. 5, pp. 1180-1194, 2014.
17. M. T. Fox, P. Harriott, B. Walker, and S. R. Stone, "Identification of potential activators of proteinase-activated receptor-2," FEBS Letters, vol. 417, no. 3, pp. 267-269, 1997.
18. M. Molino, E. S. Barnathan, R. Numerof et al., "Interactions of mast cell tryptase with thrombin receptors and PAR-2," The Journal of Biological Chemistry, vol. 272, no. 7, pp. 4043-4049, 1997.
19. I. Seitz, S. Hess, H. Schulz et al., "Membrane-type serine protease-1/matriptase induces interleukin-6 and-8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 769-775, 2007.
20. R. Ramachandran, A. Eissa, K. Mihara et al., "Proteinaseactivated receptors (PARs): differential signalling by kallikreinrelated peptidases KLK8 and KLK14," Biological Chemistry, vol. 393, no. 5, pp. 421-427, 2012.
21. D. J. Lerner, M. Chen, T. Tram, and S. R. Coughlin, "Agonist recognition by proteinase-activated receptor 2 and thrombin receptor: importance of extracellular loop interactions for receptor function," The Journal of Biological Chemistry, vol. 271, no. 24, pp. 13943-13947, 1996.
22. S. B. Elmariah, V. B. Reddy, and E. A. Lerner, "Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist," PLoS ONE, vol. 9, no. 6,Article ID e99702, 2014.
23. R. Ramachandran, K. Mihara,H. Chung et al., "Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2),"TheJournal of Biological Chemistry, vol. 286, no. 28, pp. 24638-24648, 2011.
24. M.-K. Yau, L. Liu, andD. P. Fairlie, "Toward drugs for proteaseactivated receptor 2 (PAR2)," Journal of Medicinal Chemistry, vol. 56, no. 19, pp. 7477-7497, 2013.
25. B. Al-Ani, M. Saifeddine, and M. D. Hollenberg, "Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle," Canadian Journal of Physiology and Pharmacology, vol. 73, no. 8, pp. 1203-1207, 1995.
26. M. D. Hollenberg, M. Saifeddine, and B. Al-Ani, "Proteinaseactivated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides," Molecular Pharmacology, vol. 49, no. 2, pp. 229-233, 1996.
27. M. D. Hollenberg, M. Saifeddine, B. Al-Ani, and A. Kawabata, "Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides," Canadian Journal of Physiology and Pharmacology, vol. 75, no. 7, pp. 832-841, 1997.
28. J. J. McGuire, M. Saifeddine, C. R. Triggle, K. Sun, and M. D. Hollenberg, "2-Furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist," Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 3, pp. 1124-1131, 2004.
29. G. D. Barry, J. Y. Suen, G. T. Le, A. Cotterell, R. C. Reid, and D. P. Fairlie, "Novel agonists and antagonists for human protease activated receptor 2," Journal ofMedicinal Chemistry, vol. 53,no. 20, pp. 7428-7440, 2010.
30. J. G. Seitzberg, A. E. Knapp, B. W. Lund et al., "Discovery of potent and selective small-molecule PAR-2 agonists," Journal of Medicinal Chemistry, vol. 51, no. 18, pp. 5490-5493, 2008.
31. S. Boitano, J. Hoffman, D. V. Tillu et al., "Development andevaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tethering," PLoS ONE, vol. 9, no. 6,Article ID e99140, 2014.
32. A. N. Flynn, D. V. Tillu, M. N. Asiedu et al., "The proteaseactivated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo,"The Journal of Biological Chemistry, vol. 286, no. 21, pp. 19076-19088, 2011.
33. J. Y. Suen, G. D. Barry, R. J. Lohman et al., "Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110)," British Journal of Pharmacology, vol. 165, no. 5, pp. 1413-1423, 2012.
34. S. Boitano, J. Hoffman, A. N. Flynn et al., "The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo," British Journal of Pharmacology, vol. 172, no. 18, pp. 4535-4545, 2015.
35. L. M. Sevigny, P. Zhang, A. Bohm et al., "Interdicting proteaseactivated receptor-2-driven inflammation with cell-penetrating pepducins," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 20, pp. 8491-8496, 2011.
36. A. Crilly, H. Palmer, M. B. Nickdel et al., "Immunomodulatory role of proteinase-activated receptor-2," Annals of the Rheumatic Diseases, vol. 71, no. 9, pp. 1559-1566, 2012.
37. J. Hoffman,A. N. Flynn,D. V. Tillu et al., "Lanthanide labeling of a potent protease activated receptor-2 agonist for pime-resolved fluorescence analysis," Bioconjugate Chemistry, vol. 23, no. 10, pp. 2098-2104, 2012.
38. M. D. Hollenberg, B. Renaux, E. Hyun et al., "Derivatized 2-furoyl-LIGRLO-amide, a versatile and selective probe for proteinase-activated receptor 2: Binding and visualization," Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 2, pp. 453-462, 2008.
39. E. B. Kelso, J. C. Lockhart, T. Hembrough et al., "Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation," Journal of Pharmacology and ExperimentalTherapeutics, vol. 316, no. 3, pp. 1017-1024, 2006.
40. R.-J. Lohman, A. J. Cotterell, J. Suen et al., "Antagonism of protease-activated receptor 2 protects against experimental colitis," Journal of Pharmacology and ExperimentalTherapeutics, vol. 340, no. 2, pp. 256-265, 2012.
41. J. Y. Suen, A. Cotterell, R. J. Lohman et al., "Pathway-selective antagonism of proteinase activated receptor 2," British Journal of Pharmacology, vol. 171, no. 17, pp. 4112-4124, 2014.
42. K. O'Callaghan, A. Kuliopulos, and L. Covic, "Turning receptors on and off with intracellular pepducins: new insights into Gprotein-coupled receptor drug development," The Journal of Biological Chemistry, vol. 287, no. 16, pp. 12787-12796, 2012.
43. J. J. McGuire, M. D. Hollenberg, P. Andrade-Gordon, and C. R. Triggle, "Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles," British Journal of Pharmacology, vol. 135, no. 1, pp. 155-169, 2002.
44. J. J. McGuire, "Proteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseases," Current Pharmaceutical Design, vol. 10, no. 22, pp. 2769-2778, 2004.
45. G. M. Tennant, R. M. Wadsworth, and S. Kennedy, "PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse," Atherosclerosis, vol. 198, no. 1, pp. 57-64, 2008.
46. F. Roviezzo, M. Bucci, V. Brancaleone et al., "Proteinaseactivated receptor-2 mediates arterial vasodilation in diabetes," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 25, no. 11, pp. 2349-2354, 2005.
47. T. Matsumoto, K. Ishida, K. Taguchi, T. Kobayashi, and K. Kamata, "Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery," Peptides, vol. 30, no. 9, pp. 1729-1734, 2009.
48. Y. Li, K. Mihara, M. Saifeddine et al., "Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms," British Journal of Pharmacology, vol. 164, no. 8,pp. 1990-2002, 2011.
49. Z. J. Cheng,Y.-F. Jiang, H. Ding,D. Severson, andC. R. Triggle, "Vascular dysfunction in type 2 diabetic TallyHo mice: role for an increase in the contribution of PGH2/TxA2 receptor activation and cytochrome p450 products," Canadian Journal of Physiology and Pharmacology, vol. 85, no. 3-4, pp. 404-412, 2007.
50. Y. Park, J. Yang, H. Zhang, X. Chen, and C. Zhang, "Effect of PAR2 in regulating TNF-βand NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice," Basic Research in Cardiology, vol. 106, no. 1, pp. 111-123, 2011.
51. S. Kagota, E. Chia, and J. J. McGuire, "Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice," British Journal of Pharmacology, vol. 164, no. 2, pp. 358-371, 2011.
52. S. Kagota, K. Maruyama, H. Wakuda et al., "Disturbance of vasodilation via protease-activated receptor 2 in SHRSP. ZLeprfa/ IzmDmcr rats with metabolic syndrome," Vascular Pharmacology, vol. 63, no. 1, pp. 46-54, 2014.
53. L. Howitt, M. J. Morris, S. L. Sandow, and T. V. Murphy, "Effect of diet-induced obesity on BK(Ca) function in contraction and dilation of rat isolated middle cerebral artery," Vascular Pharmacology, vol. 61, no. 1, pp. 10-15, 2014.
54. C. Wei, E. Geras-Raaka, B. Marcus-Samuels, Y. Oron, andM. C. Gershengorn, "Trypsin and thrombin accelerate aggregation of human endocrine pancreas precursor cells," Journal of Cellular Physiology, vol. 206, no. 2, pp. 322-328, 2006.
55. E. Hyun, R. Ramachandran, N. Cenac et al., "Insulin modulates protease-activated receptor 2 signaling: implications for the innate immune response," Journal of Immunology, vol. 184, no. 5, pp. 2702-2709, 2010.
56. P. Wang, Y. Jiang, Y. Wang, J. Y. Shyy, and K. A. DeFea, "Betaarrestin inhibits CAMKKbeta-dependent AMPK activation downstream of protease-activated-receptor-2," BMC Biochemistry, vol. 11, article 36, 2010.
57. L. Badeanlou, C. Furlan-Freguia, G. Yang, W. Ruf, and F. Samad, "Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation," Nature Medicine, vol. 17, no. 11, pp. 1490-1497, 2011.
58. F. Borrelli, R. Capasso, B. Severino et al., "Inhibitory effects of bromelain, a cysteine protease derived from pineapple stem (Ananas comosus), on intestinal motility in mice," Neurogastroenterology and Motility, vol. 23, no. 8, p. 745-e331, 2011.
59. A. Sumi,N. Yamanaka-Hanada, F. Bai, T. Makino,H. Mizukami, and T. Ono, "Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice," Biological and Pharmaceutical Bulletin, vol. 34, no. 6, pp. 824-830, 2011.
60. J. G. Rasmussen, S. E. Riis, O. Frøbert et al., "Activation of protease-activated receptor 2 induces VEGF independently of HIF-1," PLoS ONE, vol. 7, no. 9,Article ID e46087, 2012.
61. L. Pilgaard, P. Lund, T. Fink, and V. Zachar, "Comparative analysis of highly defined proteases for the isolation of adipose tissue-derived stem cells," Regenerative Medicine, vol. 3, no. 5, pp. 705-715, 2008.
62. P. B. Shetty, H. Tang, B. O. Tayo et al., "Variants in CXADR and F2RL1 are associated with blood pressure and obesity in African-Americans in regions identified through admixture mapping," Journal ofHypertension, vol. 30,no. 10,pp. 1970-1976, 2012.
63. J. Lim, A. Iyer, L. Liu et al., "Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism," The FASEB Journal, vol. 27, no. 12, pp. 4757-4767, 2013.
64. S. W. Görgens, K. Eckardt, M. Elsen, N. Tennagels, and J. Eckel, "Chitinase-3-like protein 1 protects skeletalmuscle from αnduced inflammation and insulin resistance," Biochemical Journal, vol. 459, no. 3, pp. 479-488, 2014.
65. N. Wronkowitz, S. W. Görgens, T. Romacho et al., "Soluble DPP4 induces inflammation and proliferation of human smoothmuscle cells via protease-activated receptor 2," Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1842, no. 9, pp. 1613-1621, 2014.
66. W. H. Yiu, D. W. L. Wong, L. Y. Y. Chan et al., "Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells," PLoS ONE, vol. 9, no. 2, Article ID e88894, 2014.
67. J. Wang, S. Chakrabarty, Q. Bui, W. Ruf, and F. Samad, "Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice," The American Journal of Pathology, vol. 185, no. 2, pp. 524-535, 2015.
68. S. Nystedt, V. Ramakrishnan, and J. Sundelin, "The proteinaseactivated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor," The Journal of Biological Chemistry, vol. 271, no. 25, pp. 14910-14915, 1996.
69. M. N. Adams, C. N. Pagel, E. J. MacKie, and J. D. Hooper, "Evaluation of antibodies directed against human protease-activated receptor-2," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 385, no. 9, pp. 861-873, 2012.
70. P. Zhao, M. Metcalf, and N. W. Bunnett, "Biased signaling of protease-activated receptors," Frontiers in Endocrinology, vol. 5, article 67, 2014.
71. N. Sitaras, J. C. Rivera, B. Noueihed et al., "Retinal neurons curb inflammation and enhance revascularization in ischemic retinopathies via proteinase-activated receptor-2," American Journal of Pathology, vol. 185, no. 2, pp. 581-595, 2014.
72. J. J. McGuire, B. N. Van Vliet, and S. J. Halfyard, "Blood pressures, heart rate and locomotor activity during salt loading and angiotensin II infusion in protease-activated receptor 2 (PAR2) knockout mice,"BMC Physiology, vol. 8, article 20, 2008.
73. J. J. McGuire, B. N. Van Vliet, J. Giménez, J. C. King, and S. J. Halfyard, "Persistence of PAR-2 vasodilation despite endothelial dysfunction in BPH/2 hypertensive mice," Pflugers Archiv, vol. 454, no. 4, pp. 535-543, 2007.
74. E. Chia, S. Kagota,E. P. Wijekoon, andJ. J. McGuire, "Protection of protease-activated receptor 2mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice," BMC Pharmacology, vol. 11, article 10, 2011.
75. B. Zhong and D. H. Wang, "Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptors," American Journal of Physiology. Regulatory, integrative and Comparative Physiology, vol. 297, no. 6, pp. R1681-R1690, 2009.
76. F. Cattaruzza, N. Cenac, E. Barocelli et al., "Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents," American Journal of Pathology, vol. 169, no. 1, pp. 177-188, 2006.
77. A. F. Milia, M. B. Salis, T. Stacca et al., "Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia," Circulation Research, vol. 91, no. 4, pp. 346-352, 2002.
78. P. G. McLean, D. Aston, D. Sarkar, andA. Ahluwalia, "Proteaseactivated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers," Circulation Research, vol. 90, no. 4, pp. 465-472, 2002.
79. C. Napoli, F. de Nigris, C. Cicala et al., "Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning," American Journal of Physiology- Heart and Circulatory Physiology, vol. 282, no. 6, pp. H2004-H2010, 2002.
80. K. Oikonomopoulou, K. K. Hansen, M. Saifeddine et al., "Kallikrein-mediated cell signalling: targeting proteinaseactivated receptors (PARs)," Biological Chemistry, vol. 387, no. 6, pp. 817-824, 2006.
81. E. P. Feener, Q. Zhou, and W. Fickweiler, "Role of plasma kallikrein in diabetes and metabolism," Thrombosis and Haemostasis, vol. 110, no. 3, pp. 434-441, 2013.
82. R. T. Abdallah, J.-S. Keum, M.-H. Lee et al., "Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors,"The Journal of Biological Chemistry, vol. 285, no. 45, pp. 35206-35215, 2010.
83. J. Robin, R. Kharbanda, P. Mclean, R. Campbell, and P. Vallance, "Protease-activated receptor 2-mediated vasodilatation in humans in vivo: role of nitric oxide and prostanoids," Circulation, vol. 107, no. 7, pp. 954-959, 2003.
84. I. J. Gudmundsdóttir, I. L. Megson, J. S. Kell et al., "Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans," Circulation, vol. 114, no. 15, pp. 1625-1632, 2006.
85. A. N. Flynn, J. Hoffman, D. V. Tillu et al., "Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering," The FASEB Journal, vol. 27, no. 4, pp. 1498-1510, 2013.
86. D. V. Tillu, S. N. Hassler, C. C. Burgos-Vega et al., "Proteaseactivated receptor 2 activation is sufficient to induce the transition to a chronic pain state," PAIN, vol. 156, no. 5, pp. 859-867, 2015.
87. S. G. Shimada, K. A. Shimada, and J. G. Collins, "Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2," European Journal of Pharmacology, vol. 530, no. 3, pp. 281-283, 2006.
88. J. Buddenkotte, C. Stroh, I. H. Engels et al., "Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B," Journal of Investigative Dermatology, vol. 124, no. 1, pp. 38-45, 2005.
89. N. Zhang andD. A. Lawrence, "Tissue factor and obesity, a twoway street," Nature Medicine, vol. 17, no. 11, pp. 1343-1344, 2011.